Cor et Vasa, 2005 (vol. 46), issue 12
Original research articles
The effect of dexrazoxane (icrf-187) administration on the incidence of late cardiotoxicity in patients treated with anthracyclins for childhood hematological malignancy: prospective echocardiographic follow-up.
Lubomír Elbl, Hana Hrstková, Iva Tomášková, Bohumír Blažek, Jaroslav Michálek
Cor Vasa 2005, 46(12):454-461
Aim of study:The authors conducted a prospective, non-randomized 8-year study designed to assess the cardioprotective effect of dexrazoxane (ICRF-187) against late myocardial injury by anthracyclins in patients treated for hematological malignancy in childhood. Patients and methods:The follow-up included 75 patients (40 boys/35 girls) aged 2-17 (median 6.5) years at the time of diagnosis. Dexrazoxane was administered before each cycle of chemotherapy with anthracyclin in 53 patients (26 boys/27 girls) and standard protocol was used in 22 patients (14 boys/8 girls). Echocardiography was undertaken prior to chemo-therapy,...
Complete myocardial arterial revascularization vs. conventional coronary artery bypass graft surgery-interim results of the CARACCASS study.
Vilém Rohn, Paul Simon, Elena Devyatko, Jana Vodičková, Jan Pirk, Ivo Skalský
Cor Vasa 2005, 46(12):463-469
Aim:The aim of the study is to furnish evidence-based medicine" data for the decision making about the type of surgical treatment of coronary heart disease. Method:CARACCASS, a prospective, multicentric, randomized study compares the outcome of complete myocardial arterial revascularization (MAR) and conventional coronary artery bypass grafting (CABG) (i. e., LIMA /left internal mammary artery/ to the LAD /left anterior descending artery/ and venous bypass) in patients with three-vessel disease. The study included a total of 763 patients aged 38-65 years. Primary endpoints include total mortality and postoperative myocardial...
Review articles
TRIADA - (TRImetazidine in stable Angina twice DAily). Evaluation of the efficacy and tolerability of Preductal MR in patients with stable angina
Václav Chaloupka
Cor Vasa 2005, 46(12):470-474
Trimetazidine (TMZ) is the first representative of a new class of antianginal agents, so called metabolic modulators, to be used in clinical practice. Essentially, its effect is based on selective inhibition of the mitochondrial fatty acid beta-oxidation enzyme 3-ketoacyl-CoA-thiolase (3-KAT). The result is partial inhibition of fatty acid oxidation and stimulation of glucose oxidation. The shift of energy generation from fatty acid beta-oxidation to aerobic glycolysis results in more effective utilization of residual oxygen in the ischemic myocardium and maintenance of macroergic phosphate formation. An advantage of TMZ is that, unlike conventional...
Case reports
Use of percutaneous left ventricular mechanical support in left main coronary artery PTCA in a patient with cardiogenic shock and acute myocardial infarction
Jan Vojáček, Josef Bis, Iva Hrubá, Pavel Polanský, Miroslav Solař, Jan Harrer, Josef Šťásek
Cor Vasa 2005, 46(12):477-482
This is a case report of a patient in cardiogenic shock associated with myocardial infarction. The patient was diagnosed to have critical complex left main coronary artery stenosis and right coronary artery occlusion. He had successful percutaneous coronary intervention with stent implantation supported by intraaortic balloon contrapulsation and percutaneous mechanical circulatory support using a Tandem Heart electromagnetic centrifugal computer-controlled pump.
Abstracts
Percutaneous left ventricular support (pVAD Tandem Heart™) in patients in cardiogenic shock: bridging to life-saving intervention-case reports of two patients.
Petr Neužil, Petr Kmoníček, Petr Niederle, Vivek Reddy, Lucie Šedivá, Miloš Táborský, Ondřej Aschermann, Roman Vopálka, Viktor Pavlíček, Lenka Pavlíčková, Jana Matoušková, Michal Paďour, Pavel Formánek, Dan Gross, Jan Petrů, Jan Škoda
Cor Vasa 2005, 46(12):484-490
We present two case reports of percutaneous left ventricular mechanical support (pVAD) in patients in acute cardiogenic shock. This percutaneously inserted system (Tandem Heart™) is intended for circulatory stabilization of patients in cardio-genic shock, who may live to have a definitive solution either by catheter-based intervention or by surgery. The system is based on the left atrium-femoral artery bypass. It makes use of a low-rate centrifugal continuous flow pump.The newly introduced pVAD system has made it possible to perform a catheter-based intervention resulting in patient circulatory stabilization and one which could be withdrawn...